Michael A Tainsky

List of Publications by Year
in descending order

98 papers	6,605 citations	108046 37 h-index	71088 80 g-index
101 all docs	101 docs citations	101 times ranked	8306 citing authors

#	Article	IF	Citations
1	Functional analysis of ATM variants in a high risk cohort provides insight into missing heritability. Cancer Genetics, 2022, 264-265, 40-49.	0.2	2
2	K3326X and Other C-Terminal BRCA2 Variants Implicated in Hereditary Cancer Syndromes: A Review. Cancers, 2021, 13, 447.	1.7	9
3	Germline mutations in apoptosis pathway genes in ovarian cancer; the functional role of a TP53I3 (PIG3) variant in ROS production and DNA repair. Cell Death Discovery, 2021, 7, 62.	2.0	7
4	Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53. Cancer Biomarkers, 2020, 27, 407-421.	0.8	18
5	FANCM, RAD1, CHEK1 and TP53I3 act as BRCA-like tumor suppressors and are mutated in hereditary ovarian cancer. Cancer Genetics, 2019, 235-236, 57-64.	0.2	17
6	Utilizing iVariantGuide for Variant Assessment of Nextâ€Generation Sequencing. Current Protocols in Bioinformatics, 2019, 65, e73.	25.8	2
7	Serum folate receptor Î± (sFR) in ovarian cancer diagnosis and surveillance. Cancer Medicine, 2019, 8, 920-927.	1.3	9
8	Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer. Genes Chromosomes and Cancer, 2018, 57, 19-27.	1.5	22
9	Germline and Somatic NF1 Alterations Are Linked to Increased HER2 Expression in Breast Cancer. Cancer Prevention Research, 2018, 11, 655-664.	0.7	4
10	Utility of paraneoplastic antigens as biomarkers for surveillance and prediction of recurrence in ovarian cancer. Cancer Biomarkers, 2017, 20, 369-387.	0.8	14
11	Paraneoplastic antigens as biomarkers for early diagnosis of ovarian cancer. Gynecologic Oncology Reports, 2017, 21, 37-44.	0.3	19
12	Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability. PLoS ONE, 2017, 12, e0178450.	1.1	39
13	Telomere dysfunction and chromothripsis. International Journal of Cancer, 2016, 138, 2905-2914.	2.3	42
14	Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors. Oncotarget, 2016, 7, 57171-57185.	0.8	21
15	Preface. Cancer and Metastasis Reviews, 2015, 34, 3-3.	2.7	0
16	Gene expression profiling of replicative and induced senescence. Cell Cycle, 2014, 13, 3927-3937.	1.3	91
17	Serum prognostic biomarkers in head and neck cancer patients. Laryngoscope, 2014, 124, 1819-1826.	1.1	7
18	RAS/MEKâ€“Independent Gene Expression Reveals BMP2-Related Malignant Phenotypes in the Nf1-Deficient MPNST. Molecular Cancer Research, 2013, 11, 616-627.	1.5	13

#	Article	IF	Citations
19	Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence. Cancer Biomarkers, 2012, 11, 59-73.	0.8	10
20	Autoantibodies as biomarkers for ovarian cancer. Cancer Biomarkers, 2011, 8, 187-201.	0.8	18
21	Higher miRNA Tolerance in Immortal Li-Fraumeni Fibroblasts with Abrogated Interferon Signaling Pathway. Cancer Research, 2011, 71, 255-265.	0.4	2
22	CREG1 enhances p16^{INK4a}-induced cellular senescence. Cell Cycle, 2011, 10, 518-530.	1.3	32
23	Epigenetic Silencing of IRF7 and/or IRF5 in Lung Cancer Cells Leads to Increased Sensitivity to Oncolytic Viruses. PLoS ONE, 2011, 6, e28683.	1.1	56
24	The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors. Molecular and Cellular Biochemistry, 2010, 344, 267-276.	1.4	14
25	Cancer Biomarker Discovery: Speed-bumps and Tire Shredders. Cancer Biomarkers, 2010, 6, 225-227.	0.8	1
26	Usage of cancer associated autoantibodies in the detection of disease. Cancer Biomarkers, 2010, 6, 257-270.	0.8	30
27	Analysis of the expression of human tumor antigens in ovarian cancer tissues. Cancer Biomarkers, 2010, 6, 33-48.	0.8	21
28	Genomic and proteomic biomarkers for cancer: A multitude of opportunities. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1796, 176-193.	3.3	66
29	Detecting tumor-specific autoantibodies for cancer diagnosis: a technology overview. Expert Opinion on Medical Diagnostics, 2009, 3, 251-261.	1.6	2
30	Predictors of decision making in families at risk for inherited breast/ovarian cancer.. Health Psychology, 2009, 28, 38-47.	1.3	20
31	Discovery of Antibody Biomarkers Using Protein Microarrays of Tumor Antigens Cloned in High Throughput. Methods in Molecular Biology, 2009, 520, 21-38.	0.4	23
32	Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene, 2008, 27, 5975-5987.	2.6	244
33	Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033. Cancer Biology and Therapy, 2008, 7, 1938-1946.	1.5	16
34	Interferon Regulatory Factors IRF5 and IRF7 Inhibit Growth and Induce Senescence in Immortal Li-Fraumeni Fibroblasts. Molecular Cancer Research, 2008, 6, 770-784.	1.5	48
35	Spatial Detrending and Normalization Methods for Two-Channel DNA and Protein Microarray Data. Drug Discovery Series, 2008, , 61-80.	0.1	0
36	Autoantibody Approach for Serum-Based Detection of Head and Neck Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2396-2405.	1.1	69

#	Article	IF	Citations
37	Pathways to implementation of serum proteomics for cancer. Expert Opinion on Medical Diagnostics, 2007, 1, 3-15.	1.6	0
38	Update on ovarian cancer screening. Current Opinion in Obstetrics and Gynecology, 2007, 19, 22-26.	0.9	40
39	Evidence that Tumor Necrosis Factorâ€"Related Apoptosis-Inducing Ligand Induction by 5-Aza-2â€²-Deoxycytidine Sensitizes Human Breast Cancer Cells to Adriamycin. Cancer Research, 2007, 67, 1203-1211.	0.4	52
40	Epigenetic and functional analysis of IGFBP3 and IGFBPrP1 in cellular immortalization. Biochemical and Biophysical Research Communications, 2007, 357, 785-791.	1.0	16
41	Sphingomyelin synthase 1 suppresses ceramide production and apoptosis post-photodamage. Biochemical and Biophysical Research Communications, 2007, 358, 196-202.	1.0	47
42	Multianalyte Tests for the Early Detection of Cancer: Speedbumps and Barriers. Biomarker Insights, 2007, 2, 117727190700200.	1.0	2
43	Mutations in SIRT2 deacetylase which regulate enzymatic activity but not its interaction with HDAC6 and tubulin. Molecular and Cellular Biochemistry, 2007, 303, 221-230.	1.4	69
44	Microtubule Deacetylases, SirT2 and HDAC6, in the Nervous System. Neurochemical Research, 2007, 32, 187-195.	1.6	117
45	Multianalyte tests for the early detection of cancer: speedbumps and barriers. Biomarker Insights, 2007, 2, 261-7.	1.0	1
46	Stat1 Expression Is Not Sufficient to Regulate the Interferon Signaling Pathway in Cellular Immortalization. Journal of Interferon and Cytokine Research, 2006, 26, 14-26.	0.5	6
47	Direct production and purification of T7 phage display cloned proteins selected and analyzed on microarrays. BioTechniques, 2006, 40, 220-227.	0.8	10
48	Expression Profiling Identifies Three Pathways Altered in Cellular Immortalization: Interferon, Cell Cycle, and Cytoskeleton. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2006, 61, 879-889.	1.7	24
49	Communication and decision-making about seeking inherited cancer risk information: findings from female survivor-relative focus groups. Psycho-Oncology, 2006, 15, 193-208.	1.0	55
50	Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1. Biochemical Pharmacology, 2006, 72, 1485-1492.	2.0	39
51	Stochastic cancer progression driven by non-clonal chromosome aberrations. Journal of Cellular Physiology, 2006, 208, 461-472.	2.0	143
52	Antioxidant agents transiently inhibit aneuploidy progression in Li-Fraumeni cell strains. Molecular Carcinogenesis, 2006, 45, 141-156.	1.3	8
53	The Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor PD184352 (CI-1040) Selectively Induces Apoptosis in Malignant Schwannoma Cell Lines. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 456-465.	1.3	63
54	Diagnostic Markers of Ovarian Cancer by High-Throughput Antigen Cloning and Detection on Arrays. Cancer Research, 2006, 66, 1181-1190.	0.4	199

#	Article	IF	Citations
55	Epitomics: Global Profiling of Immune Response to Disease Using Protein Microarrays. OMICS A Journal of Integrative Biology, 2006, 10, 499-506.	1.0	25
56	Immunotheranostics: breaking tolerance in immunotherapy using tumor autoantigens identified on protein microarrays. Current Opinion in Drug Discovery & Development, 2006, 9, 380-5.	1.9	11
57	Docetaxel Associated Pathways in Cisplatin Resistant Head and Neck Squamous Cell Carcinoma: A Pilot Study. Laryngoscope, 2005, 115, 1938-1946.	1.1	10
58	Epitomics: serum screening for the early detection of cancer on microarrays using complex panels of tumor antigens. Expert Review of Molecular Diagnostics, 2005, 5, 735-743.	1.5	37
59	A role for manganese superoxide dismutase in apoptosis after photosensitization. Biochemical and Biophysical Research Communications, 2005, 332, 411-417.	1.0	40
60	De Novo Ceramide Accumulation Due to Inhibition of Its Conversion to Complex Sphingolipids in Apoptotic Photosensitized Cells. Journal of Biological Chemistry, 2004, 279, 23238-23249.	1.6	54
61	Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by overexpression of AP-2Î±. Oncogene, 2004, 23, 5496-5504.	2.6	26
62	Breast cancer genetics in African Americans. Cancer, 2003, 97, 236-245.	2.0	153
63	Epigenetic silencing of multiple interferon pathway genes after cellular immortalization. Oncogene, 2003, 22, 4118-4127.	2.6	127
64	Functional characterization of the interacting domains of the positive coactivator PC4 with the transcription factor AP-2Î±. Gene, 2003, 320, 155-164.	1.0	14
65	Role for Human SIRT2 NAD-Dependent Deacetylase Activity in Control of Mitotic Exit in the Cell Cycle. Molecular and Cellular Biology, 2003, 23, 3173-3185.	1.1	449
66	Onto-Tools, the toolkit of the modern biologist: Onto-Express, Onto-Compare, Onto-Design and Onto-Translate. Nucleic Acids Research, 2003, 31, 3775-3781.	6.5	319
67	Noise sampling method: an ANOVA approach allowing robust selection of differentially regulated genes measured by DNA microarrays. Bioinformatics, 2003, 19, 1348-1359.	1.8	54
68	Assessing the Functional Bias of Commercial Microarrays Using the Onto-Compare Database. BioTechniques, 2003, 34, S55-S61.	0.8	13
69	Ethnic differences in survival among women with ovarian carcinoma. Cancer, 2002, 94, 1886-1893.	2.0	61
70	Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clinical Cancer Research, 2002, 8, 3910-21.	3.2	57
71	Characterization of the Activation Domains of AP-2 Family Transcription Factors. Journal of Biological Chemistry, 2000, 275, 29701-29708.	1.6	56
72	PolyADP-ribose polymerase is a coactivator for AP-2-mediated transcriptional activation. Nucleic Acids Research, 1999, 27, 866-874.	6.5	135

#	Article	IF	Citations
73	Coactivator PC4 Mediates AP-2 Transcriptional Activity and Suppresses ras-Induced Transformation Dependent on AP-2 Transcriptional Interference. Molecular and Cellular Biology, 1999, 19, 899-908.	1.1	57
74	Telomerase activity during spontaneous immortalization of Li-Fraumeni syndrome skin fibroblasts. Oncogene, 1998, 17, 709-717.	2.6	53
75	Cloning and characterization of the Drosophila homologue of the AP-2 transcription factor. Oncogene, 1998, 17, 1911-1922.	2.6	29
76	pZ402, an improved SV40-based shuttle vector containing a T-antigen mutant unable to interact with wild-type p53. Gene, 1998, 211, 229-234.	1.0	3
77	Loss of AP-2 Results in Up-regulation ofMCAM/MUC18 and an Increase in Tumor Growth and Metastasis of Human Melanoma Cells. Journal of Biological Chemistry, 1998, 273, 16501-16508.	1.6	141
78	drp, a Novel Protein Expressed at High Cell Density but Not During Growth Arrest. DNA and Cell Biology, 1998, 17, 437-447.	0.9	22
79	Coordinate control of growth and cytokeratin 13 expression by retinoic acid. Molecular Carcinogenesis, 1996, 16, 6-11.	1.3	4
80	Genomic instability due to germline p53 mutations drives preneoplastic Progression toward cancer in human cells. Cancer and Metastasis Reviews, 1995, 14, 43-48.	2.7	33
81	Aflatoxin B1-induced immortalization of cultured skin fibroblasts from a patient with Li-Fraumeni syndrome. Carcinogenesis, 1995, 16, 25-34.	1.3	32
82	Molecular phenotyping of head and neck cancer. Cancer Treatment and Research, 1995, 74, 17-42.	0.2	1
83	The genomic structure of the human AP-2 transcription factor. Nucleic Acids Research, 1994, 22, 1413-1420.	6.5	62
84	N-ras oncogene causes AP-2 transcriptional self-interference, which leads to transformation.. Genes and Development, 1994, 8, 1258-1269.	2.7	89
85	The Liâ€“Fraumeni Syndrome: From Clinical Epidemiology to Molecular Genetics. American Journal of Epidemiology, 1992, 135, 190-199.	1.6	78
86	Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 1992, 70, 937-948.	13.5	1,116
87	The effect of retinoic acid on chemosensitivity of PA-1 human teratocarcinoma cells and its modulation by an activatedN-ras oncogene. International Journal of Cancer, 1992, 51, 646-651.	2.3	17
88	The H-ras oncogene regulates expression of 70- and 45-kDa cell-surface molecules whose expression correlates with tumor-cell immunogenicity. International Journal of Cancer, 1992, 52, 329-335.	2.3	4
89	Elevated expression of the ribosomal protein S2 gene in human tumors. Molecular Carcinogenesis, 1992, 5, 219-231.	1.3	59
90	Ras gene mutation and amplification in human nonmelanoma skin cancers. Molecular Carcinogenesis, 1991, 4, 196-202.	1.3	250

#	Article	IF	Citations
91	Preparation of High-Molecular-Weight DNA for Use in DNA Transfection: Secondary Transfections for Cloning Active Genes by Direct Phenotypic Selection. , 1991, 7, 91-98.		0
92	Susceptibility forN-ras-mediated transformation requires loss of tumor suppressor activity. Somatic Cell and Molecular Genetics, 1990, 16, 15-27.	0.7	7
93	The current state of oncogenes and cancer: Experimental approaches for analyzing oncogenetic events in human cancer. Cancer and Metastasis Reviews, 1990, 9, 63-80.	2.7	19
94	Molecular cloning of the Mason-Pfizer monkey virus genome: Biological characterization of genome length clones and molecular comparisons to other retroviruses. Virology, 1986, 153, 201-214.	1.1	14
95	Analysis of the transforming potential of the human homolog of mos. Cell, 1986, 46, 785-794.	13.5	26
96	Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature, 1984, 311, 29-33.	13.7	923
97	REGULATION OF DNA-DEPENDENT: RNA POLYMERASE I ACTIVITY IN RAT LIVER NUCLEI. , 1978, , 525.		0
98	Enhanced quaternary stability of Î²4 hemoglobin in 2 m-sodium chloride. Journal of Molecular Biology, 1973, 75, 735-739.	2.0	26